Δ-8-Tetrahydrocannabinol
Viewing r1.a1 — Oct 2, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Δ8-THC (Δ-8-tetrahydrocannabinol) is a synthetic cannabinoid of the terpenophenolic class. It is a positional isomer of Δ9-THC, differing by a single double bond and producing milder psychoactive effects. Δ8-THC is a partial agonist at CB1 receptors, producing its effects by inhibiting neurotransmitter release through retrograde endocannabinoid signaling.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
First synthesized by Roger Adams around 1941 and isolated from cannabis in 1966, Δ8-THC remained a pharmacological footnote until Mechoulam demonstrated complete suppression of chemotherapy-induced vomiting in pediatric patients in 1995.[2][3][4] Following the 2018 U.S. Farm Bill, acid-catalyzed conversion of hemp CBD into Δ8-THC created a booming consumer market now facing federal legislative closure.[5]
Subjective effects include relaxation, mild euphoria, appetite enhancement, and anxiolysis. The experience is consistently described as a clearer-headed, less anxiety-prone version of Δ9-THC — a cannabinoid high with a wider comfortable dose window.[6] Memory impairment, dry mouth, and increased heart rate are common unsought effects.
Δ8-THC produces physical dependence through CB1 downregulation, and no lethal dose has been established in any species.[7] The dominant real-world risk is product contamination — uncharacterized synthesis byproducts in commercial products far exceed labeled impurity levels.[8] No validated human pharmacokinetic data have been published; controlled trial results from Johns Hopkins await release.[9][10]
History[edit]
Discovery
Roger Adams at the University of Illinois synthesized Δ8-THC around 1941 during early structural investigations of cannabis constituents, working with Minnesota wild hemp and the U.S. Treasury Department Narcotics Laboratory.[3] The compound was first isolated from naturally grown cannabis in 1966, appearing in very low yield from Maryland-cultivated marijuana.[4]
Clinical Significance
The compound's most notable clinical application came from Raphael Mechoulam's group in Jerusalem. Between 1987 and 1995, eight children with hematologic cancers received Δ8-THC before chemotherapy — across 480 treatment sessions, vomiting was completely prevented with negligible psychotropic adverse effects compared to Δ9-THC.[2] This uncontrolled study remains the primary clinical evidence for Δ8-THC's antiemetic potential.
Commercial Expansion and Regulatory Response
The 2018 U.S. Farm Bill defined legal hemp as cannabis containing ≤0.3% Δ9-THC, inadvertently creating a loophole for CBD-derived Δ8-THC products.[5] The market exploded between 2019 and 2021 — vape cartridges, gummies, and tinctures became core revenue for hemp processors. The CDC issued a health advisory in September 2021 after recording 2,362 poison control exposures, and 2025 federal legislation closed the loophole effective November 2026.[11][12]
The "Δ8" designation refers to the position of the carbon-carbon double bond (between C8 and C9) in the cyclohexene ring — a naming convention from classical terpenoid chemistry. In consumer culture, Δ8-THC earned the informal label "diet weed" or "legal THC," reflecting both its reduced potency relative to Δ9-THC and its availability in U.S. states where cannabis remained prohibited.
Chemistry[edit]
Structure
Δ-8-Tetrahydrocannabinol belongs to the terpenophenolic cannabinoid family, sharing the tricyclic dibenzopyran scaffold common to all classical cannabinoids. The molecule consists of a phenolic A-ring, a cyclohexene C-ring, and a central pyran B-ring with a pentyl side chain at C-3.
The single structural difference from Δ9-THC is the position of the C-ring double bond: between C8 and C9 rather than C9 and C10.[4] This one-bond shift reduces CB1 affinity but increases chemical stability.
Molecular Properties
| Molecular formula | C₂₁H₃₀O₂ |
| Molecular weight | 314.5 g/mol |
Key functional groups include a phenolic hydroxyl at C-1 (essential for receptor binding), geminal dimethyl groups at C-6 contributing to lipophilicity, and a methyl group at C-9 adjacent to the defining double bond.
Stereochemistry
The pharmacologically active form is (−)-trans-Δ8-THC with (6aR,10aR) absolute configuration, directly analogous to the stereochemistry of natural Δ9-THC.[4] The opposite enantiomer shows substantially reduced receptor binding.
Stability
The Δ8 double bond position is more thermodynamically stable than the Δ9 position, conferring greater resistance to oxidation and longer shelf life.[4] This is why Δ8-THC accumulates as a degradation product of Δ9-THC during storage.
Stability is pH-dependent: significant degradation occurs in strongly acidic conditions (pH 1.2, simulating gastric acid) while the compound remains stable at physiological pH.[14]
Synthesis
Commercial Δ8-THC is produced via acid-catalyzed isomerization of CBD, a reaction first described by Gaoni and Mechoulam in 1966.[4] Modern production uses various acid catalysts under reflux, generating Δ8-THC alongside numerous byproducts including Δ9-THC, cannabinol, hydroxylated hexahydrocannabinols, and novel cannabinoid analogs with unknown safety profiles.[15][8]
Pharmacology[edit]
Mechanism of Action
Δ-8-Tetrahydrocannabinol is a partial agonist at the CB1, the primary mediator of cannabinoid psychoactivity.[1] When Δ8-THC binds CB1, it triggers Gi/o protein signaling that reduces cellular cAMP levels, modulates calcium and potassium ion channels, and activates the arachidonic acid cascade leading to prostaglandin E₂ production.[16]
A distinctive finding is that cyclooxygenase inhibitors (indomethacin, aspirin, diclofenac) antagonize Δ8-THC-induced behavioral suppression in rats, suggesting prostaglandin E₂ contributes directly to sedative effects.[16] The compound also activates CB2 receptors on immune cells, though this has been less extensively characterized.[1]
All psychoactive effects are confirmed CB1-mediated: the selective CB1 blocker rimonabant completely abolishes Δ8-THC's behavioral profile in preclinical models.[7]
Pharmacokinetics
No validated human pharmacokinetic parameters for Δ8-THC have been published as of May 2026. Controlled trials at Johns Hopkins (NCT05287256) include pharmacokinetic measurements, but results await publication.[9][10] Values below derive from rat studies.In rats, intravenous administration yields a long terminal half-life (approximately 14 hours) and extensive tissue distribution consistent with high lipophilicity.[17] Oral bioavailability from oil is very low (approximately 3%), reflecting heavy first-pass liver metabolism.[17] Nanoemulsion formulations improve oral absorption to 11–16.5% with faster onset.[18]
The compound penetrates the brain readily and is detectable in rat brain tissue 24 hours after a single oral dose. Repeated daily dosing produces plasma accumulation over 14 days.[19]
Metabolism
The primary metabolic pathway produces 11-hydroxy-Δ8-THC, a pharmacologically active metabolite with CB1 agonist activity analogous to 11-OH-Δ9-THC.[18] Further oxidation yields 11-nor-9-carboxy-Δ8-THC, an inactive metabolite and the primary urinary marker.[20]
By structural analogy with Δ9-THC, metabolism is expected to proceed primarily through CYP3A4 and CYP2C9/2C19 enzymes.[21] No Δ8-THC-specific metabolism studies have been published. This enzyme profile creates potential for drug interactions with medications metabolized by the same pathways.[21]
Neuroscience[edit]
Where It Acts
Δ8-THC hijacks the endocannabinoid system — a retrograde signaling network where endogenous compounds (anandamide and 2-AG) travel backward across synapses to suppress neurotransmitter release.[22] Where endocannabinoids activate this brake selectively based on neural activity, Δ8-THC activates it indiscriminately across circuits.
In the hippocampus, this suppresses memory encoding. In the amygdala, it damps fear responses at low doses but can disrupt prefrontal regulation at high doses. In the hypothalamus, it drives appetite. In reward pathways, it produces reinforcement qualitatively similar to Δ9-THC.[7][6]
Why It Matters
The bidirectional anxiety model is the most explanatory framework for Δ8-THC's appeal: low CB1 occupancy preferentially modulates inhibitory interneurons in the amygdala (reducing anxiety), while high occupancy disrupts top-down prefrontal control (producing anxiety).inferred Because Δ8-THC has lower CB1 affinity than Δ9-THC, it offers a wider dose window before crossing into anxiogenic territory — explaining consumer reports of "clearer-headed" effects.[6]
A distinctive mechanistic finding is prostaglandin E₂ mediation: COX inhibitors block Δ8-THC behavioral effects in rats, suggesting an arachidonic acid pathway contribution to sedation not extensively studied for other cannabinoids.[16]
No human neuroimaging studies (fMRI, PET, EEG) of Δ8-THC have been published. Whether its neural signature diverges meaningfully from Δ9-THC — particularly in default mode network modulation — is unknown.
Subjective Effects[edit]
The Δ8-THC experience occupies the lower-intensity end of the cannabinoid spectrum. At threshold and light doses, users report subtle mood lift and physical relaxation without cognitive impairment. As dose increases, the experience deepens into recognizable cannabis territory — warmth, appetite stimulation, time dilation, and mild perceptual softening — but retains a clarity and composure that distinguishes it from equivalent subjective doses of Δ9-THC.[6] Set and setting modulate hedonic valence strongly, particularly anxiety susceptibility.
Relative to Δ9-THC, the experience is best understood as the same instrument played at lower volume: qualitatively similar effects with a wider window between pleasant and overwhelming. Users who find Δ9-THC too anxiety-prone or cognitively disorienting often describe Δ8-THC as occupying the space they intended cannabis to fill.
Effect Grid
Clear cannabinoid intoxication is present. Euphoria and relaxation are the dominant features — a warm, pleasant cognitive glow paired with noticeable body high and muscle relaxation. Appetite enhancement is reliable. Nausea suppression is effective at this range, consistent with Mechoulam's antiemetic findings.
Cognitive effects become apparent: mild thought deceleration, short-term memory suppression, and subtle time alteration. Focus suppression makes complex tasks more difficult. These cognitive changes are consistently described as less impairing than equivalent Δ9-THC doses. Humor enhancement and music enhancement may emerge.
Anxiolytic effects are typical at this tier. Motor control impairment is mild but present — driving is unsafe. Dry mouth is common. Sedation increases toward the offset phase.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Color alteration · Depth perception distortion · Perspective distortion · Sound sensitivity · Spatial disorientation · Touch enhancement · Auditory misinterpretation · Proprioceptive distortion · Vestibular distortion · Olfactory enhancement · Auditory distortion · Visual haze / noise · Visual processing suppression
Spatial disorientation · Touch enhancement · Auditory misinterpretation · Proprioceptive distortion · Vestibular distortion · Olfactory enhancement · Auditory distortion · Visual haze / noise · Visual processing suppression
Appetite enhancement · Bodily heaviness · Heart rate perception changes · Laughter fits · Muscle relaxation · Sedation · Dizziness · Pain suppression · Physical fatigue · Spontaneous body sensations · Tactile euphoria · Body schema distortion · Stimulation · Bodily lightness · Constipation · Headache · Insomnia · Nystagmus (eye wobbles) · Restlessness · Sexual arousal enhancement · Sexual arousal suppression · Temperature dysregulation · Tingling / electric sensations · Wakefulness · Nausea · Vomiting · Bodily dissociation
Laughter fits · Muscle relaxation · Sedation · Dizziness · Pain suppression · Physical fatigue · Spontaneous body sensations · Tactile euphoria · Body schema distortion · Stimulation · Bodily lightness · Constipation · Headache · Insomnia · Nystagmus (eye wobbles) · Restlessness · Sexual arousal enhancement · Sexual arousal suppression · Tingling / electric sensations · Wakefulness · Nausea · Vomiting · Bodily dissociation
Aesthetic enhancement · Cognitive euphoria · Conceptual thinking · Focus suppression · Immersion enhancement · Information processing suppression · Memory fragmentation · Novelty enhancement · Thought disorganization · Humor enhancement · Analysis suppression · Cognitive fatigue · Confusion · Creativity enhancement · Introspection enhancement · Multiple thought streams · Openness enhancement · Thought deceleration · Thought loops · Cognitive dysphoria · Cognitive flexibility · Compulsive redosing urge · Language suppression · Motivation suppression · Pattern recognition enhancement · Thought acceleration · Delusions of sobriety · Synchronicity · Motivation enhancement · Amnesia
Focus suppression · Immersion enhancement · Information processing suppression · Memory fragmentation · Novelty enhancement · Thought disorganization · Humor enhancement · Analysis suppression · Cognitive fatigue · Confusion · Creativity enhancement · Introspection enhancement · Multiple thought streams · Openness enhancement · Thought deceleration · Thought loops · Cognitive dysphoria · Cognitive flexibility · Language suppression · Motivation suppression · Pattern recognition enhancement · Thought acceleration · Delusions of sobriety · Synchronicity · Motivation enhancement · Amnesia
Emotional lability · Dysphoria · Irritability · Simultaneous emotions
Craving · Depersonalization · Derealization · Trust enhancement · Communication enhancement · Flow state · Communication suppression · Compulsive behavior reduction · Sociability suppression · Social disconnection · Cognitive disconnection · Boundary dissolution
Communication enhancement · Flow state · Communication suppression · Compulsive behavior reduction · Sociability suppression · Social disconnection · Cognitive disconnection · Boundary dissolution
Timeline
Gradual awareness of subtle body warmth and a faint mood shift. Effects may be barely perceptible for the first 30–60 minutes; oral onset is slow and highly variable depending on stomach contents and formulation.
Progressive deepening of relaxation as euphoria emerges. Appetite signals strengthen, body high becomes noticeable. Cognitive pace begins to slow.
Full cannabinoid effect — warm euphoria, deep relaxation, appetite enhancement, time alteration, and short-term memory suppression. Cognitive impairment and sedation are at their maximum. Anxiety is possible at higher doses.
Gradual reduction in cognitive effects while body relaxation and sedation linger. Appetite enhancement may persist. Drowsiness increases toward the end of this phase.
Residual sedation, mild appetite enhancement, and subtle mood softening. Cognitive function returns to near-baseline but subclinical impairment may persist for hours.
⚠ Avoid driving for at least 6 hours after oral use, or longer if sedation persists.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 21 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Low
- Dose escalation
- Moderate
- Cross-tol.
- Δ9-THC · WIN 55,212-2 · Synthetic cannabinoids (CB1 agonists)
Toxicity
No lethal dose has been established for Δ8-THC in any species, and no human fatalities have been directly attributed to the compound in published literature.safety citation needed The therapeutic index is presumed very high, consistent with the cannabinoid class.
Acute Toxicity
FDA adverse event analysis identified 104 Δ8-THC reports between December 2020 and February 2022; 55% required emergency intervention or hospital admission.[23] The CDC recorded 2,362 poison control exposures in a similar period, with 41% involving patients under 18.[11]
Reported adverse effects include hallucinations, vomiting, tremor, anxiety, dizziness, and confusion.[24]
Pediatric Toxicity
Children under 6 are particularly vulnerable to serious adverse events from accidental ingestion of Δ8-THC edibles.[25] Multiple pediatric patients have presented unconscious and unresponsive — loss of consciousness is a consistent finding in severe pediatric cases that does not typically occur in adults at equivalent weight-adjusted doses.[5]
Product Contamination
Laboratory analysis found impurities far exceeding declared levels — one product contained over 15% non-Δ8-THC material.[8] Contaminants include novel cannabinoid analogs with unknown safety profiles, residual solvents, acidic catalysts, heavy metals, and pesticides from CBD source material.[8][15] The FDA has noted that some manufacturers may use unsafe household chemicals in production.[12]
No long-term safety data exist for commercial products with their actual impurity profiles.safety citation needed
Psychological Risks
At typical doses, Δ8-THC produces lower rates of anxiety and paranoia compared to equivalent subjective doses of Δ9-THC.[6] At high doses — particularly in naive users or pediatric exposures — anxiety, paranoia, hallucinations, confusion, and loss of consciousness have been reported.[11][24]
No Δ8-THC-specific data exist on cannabis-induced psychosis. By class inference, sufficient CB1 agonist exposure can trigger transient psychotic symptoms and derealization — expected to be attenuated relative to Δ9-THC due to lower CB1 affinity, but not independently quantified.inferred
Cannabinoid hyperemesis syndrome has not been specifically documented with Δ8-THC but represents a class risk with heavy chronic CB1 agonist use.inferred
Tolerance & Dependence
Tolerance develops through CB1 receptor downregulation. In mice, repeated Δ8-THC administration at 50 mg/kg produced tolerance to all cannabimimetic effects: sedation, pain suppression, temperature reduction, and locomotor suppression.[7] Cross-tolerance with synthetic cannabinoids confirms a shared CB1 mechanism.[7]
Physical dependence is demonstrated: the CB1 blocker rimonabant precipitates withdrawal (jumping, paw tremors, altered behavior) after repeated Δ8-THC dosing in mice.[7] No human withdrawal data exist; by class inference from Δ9-THC, chronic heavy use would produce irritability, sleep disturbance, appetite suppression, and low mood upon cessation.inferred
Δ8-THC produces Δ9-THC-like reinforcement in preclinical models, indicating similar abuse potential.[7] Cannabis use disorder criteria are expected to apply to heavy use patterns.inferred
Drug Interactions
Metabolic Interactions
Δ8-THC is expected to be metabolized via CYP3A4, CYP2C9, and CYP2C19.[21] Clinically significant interactions are predicted with:
- Warfarin — potential for increased bleeding risk via CYP2C9 interaction. This is a narrow-therapeutic-index drug requiring monitoring.[21]
- Immunosuppressants (tacrolimus, cyclosporine) — CYP3A4 competition may alter blood levels.[21]
- Clopidogrel — CYP2C19 competition may reduce activation of this blood thinner.[21]
Additive Effects
Additive sedation is expected with alcohol, benzodiazepines, opioids, other cannabinoids, and sedating antihistamines. CB1 agonism produces early heart rate increase followed by slowing; combination with stimulants (amphetamines, cocaine) may produce additive cardiovascular stress.inferred
Contraindications
- Psychotic disorders — CB1 agonism can precipitate or worsen psychotic symptoms. History of schizophrenia, schizoaffective disorder, or first-degree family history of psychosis represents elevated risk.inferred
- Heart conditions — CB1-mediated heart rate changes may be clinically significant in coronary artery disease, arrhythmias, or recent cardiac events.inferred
- Pregnancy and breastfeeding — cannabinoids cross the placenta and are present in breast milk. Developmental effects documented for Δ9-THC are expected to apply.inferred
- Blood thinners — potential CYP2C9 interaction with warfarin.[21]
- Liver impairment — high first-pass metabolism suggests altered exposure in hepatic disease.inferred
- Children — documented severe adverse events including loss of consciousness.[5][25]
Harm Reduction[edit]
Forms & Identification
The primary harm with Δ8-THC is not the compound itself but what accompanies it in commercial products. Because virtually all Δ8-THC is synthesized from CBD via acid-catalyzed isomerization, product quality depends entirely on the manufacturer’s purification process — and independent testing consistently shows Certificates of Analysis understate impurity content.
Third-party lab reports showing cannabinoid profiles (not just potency) are the minimum standard. Look for full panel testing that includes residual solvents, heavy metals, and pesticides. Products listing only Δ8-THC percentage without a breakdown of other cannabinoids present are a red flag.
Guidelines
- Start with the lowest available dose, especially with edibles where onset is delayed 45–90 minutes
- Do not redose oral preparations within 2 hours — delayed onset leads to accidental overconsumption
- Keep products in child-resistant packaging and out of reach — pediatric edible ingestion is a documented emergency
- Test products through independent labs when possible; distrust potency claims on unregulated products
- Avoid driving or operating machinery — Δ8-THC impairs reaction time and coordination
- If using for the first time, have a sober companion present
Set & Setting
Despite its reputation as milder than Δ9-THC, Δ8-THC is still a psychoactive CB1 agonist. First-time users, those with low cannabinoid tolerance, and anyone switching from a different product or batch should treat each experience as potentially novel.
A familiar, comfortable environment reduces anxiety susceptibility. The substance's dose-response curve includes a threshold beyond which anxiety and paranoia emerge — a lower-stress setting raises that threshold.
Aftercare & integration. Δ8-THC does not typically produce experiences requiring formal integration. For those who experienced anxiety, paranoia, or dissociation:
- Allow 24–48 hours before assessing whether to use again
- Hydrate and eat normally — appetite disturbance after heavy use is common
- If anxiety persists beyond 24 hours, reduce dose or discontinue
- Grounding techniques (cold water on face, naming objects in the room, physical movement) help with residual dissociation
For regular users noticing tolerance escalation, a 48–72 hour break allows partial CB1 receptor resensitization. Longer breaks (2–4 weeks) produce more complete tolerance reset.
Recovery & Support
Cannabinoid dependence develops gradually. Signs include using more than intended, unsuccessful attempts to cut back, continued use despite negative consequences, and withdrawal discomfort (irritability, insomnia, appetite suppression) when stopping.
Cannabis use disorder treatment approaches apply to Δ8-THC dependence. Cognitive-behavioral therapy and motivational enhancement have the strongest evidence base. No pharmacotherapy is approved for cannabinoid withdrawal, but symptom management (sleep aids, gradual taper) can ease the process.
Support resources include SAMHSA’s National Helpline (1-800-662-4357), Marijuana Anonymous, and local addiction services. Seeking help is appropriate whenever use feels compulsive rather than chosen.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
Most Δ8-THC experiences, even uncomfortable ones, resolve without medical intervention. Seek immediate help if:
- Loss of consciousness or inability to be roused
- Seizure activity
- Severe chest pain or irregular heartbeat
- Psychotic symptoms (complete loss of contact with reality, self-harm behavior)
- Any pediatric ingestion — children can deteriorate rapidly
Immediate steps:
- Call emergency services if any of the above are present
- Place an unconscious person in the recovery position (on their side, airway clear)
- Do NOT induce vomiting
- Stay with the person — reassure and keep them calm if conscious
- Remove dangerous objects from the environment if psychotic behavior is present
What to tell the dispatcher:
Substance consumed (Δ8-THC), approximate amount, time of consumption, current symptoms, and age/weight of the person. Good Samaritan laws in many jurisdictions protect people who call for help during drug-related emergencies.
Legal Status[edit]
Overview
Δ8-THC occupies a uniquely fragmented legal position: a trace natural cannabinoid that became a mass-market product through chemical synthesis from hemp CBD. This dual identity produced years of regulatory ambiguity in the United States, while most international jurisdictions with THC structural analog provisions treat it as equivalent to Δ9-THC.inferred
Jurisdictions
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Schedule I (CSA); Farm Bill gap closing 2026 | Δ8-THC classified as Schedule I analog of Δ9-THC. 2018 Farm Bill created regulatory gap for hemp-derived products (≤0.3% Δ9-THC). 2025 legislation (effective November 12, 2026) closes loophole by excluding cannabinoids produced by chemical synthesis or conversion.[5][12] FDA declares Δ8-THC products not GRAS. |
| United States (state-level) | Variable: permitted, restricted, or banned | Approximately 30 states permitted Δ8-THC sales with varying regulation as of 2026. States with legal recreational cannabis show lower Δ8-THC use; prohibition states show higher uptake.[26][13] |
| United Kingdom | Presumed controlled (THC analog)citation needed | Under the Misuse of Drugs Act 1971, THC isomers are broadly controlled as Class B substances. |
| European Union | Variable by member statecitation needed | No EU-wide Δ8-THC-specific regulation. Member states with THC analog provisions classify it equivalently to Δ9-THC. |
| Canada | Presumed controlled (Cannabis Act)citation needed | The Cannabis Act controls THC and its isomers. Δ8-THC falls under general THC scheduling. |
| Australia | Presumed Schedule 9 (THC analog)citation needed | Australian Poisons Standard lists tetrahydrocannabinols broadly. |
Regulatory Trajectory
The U.S. regulatory arc follows a pattern common to novel psychoactive substances in scheduling gray areas: rapid commercial expansion during ambiguity, public health concern (2,362 poison control cases, CDC health advisory), and eventual legislative closure.[11]
The 2025 federal legislation targeting CBD-derived cannabinoids is expected to substantially reduce legal Δ8-THC product availability after November 2026.[12]
references
- [1] ^abcTagen M, Klumpers LE (2022) Review of delta-8-tetrahydrocannabinol (Δ8-THC): Comparative pharmacology with Δ9-THC — British Journal of Pharmacology doi:10.1111/bph.15865
- [2] ^abAbrahamov A, Abrahamov A, Mechoulam R (1995) An efficient new cannabinoid antiemetic in pediatric oncology — Life Sciences PMID:7776837
- [3] ^abFiler CN (2020) Minnesota wild hemp: a crucial botanical source in early cannabinoid discovery — Journal of Cannabis Research doi:10.1186/s42238-020-00031-3
- [4]
- [5]
- [6]